Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of...
April 17 2015 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the upcoming presentation of two
posters comparing gene expression profiles and additional methods
used to show equivalence between GlatopaTM and daily COPAXONE® 20
mg (glatiramer acetate injection). The posters will be presented at
the 67th AAN Annual Meeting taking place April 18 – 25, 2015 in
Washington, D.C.
Poster Presentation Details
Title: Comparative Gene Expression Profiling between a Generic
(Glatopa) and Brand COPAXONE (glatiramer acetate injection) Poster
Number: P1.144 Presentation Date/Time: Monday, April 20, 2015; 2:00
p.m. – 6:30 p.m. EDT
Title: Demonstration of Equivalence between a Generic (Glatopa)
and Brand COPAXONE (glatiramer acetate injection) Poster Number:
P1.145 Presentation Date/Time: Monday, April 20, 2015; 2:00 p.m. –
6:30 p.m. EDT
About GlatopaTM Once daily
Glatopa (glatiramer acetate injection), developed in collaboration
with Sandoz, is the first FDA-approved generic version of daily
COPAXONE® 20 mg for patients with relapsing forms of multiple
sclerosis. Produced entirely in the United States, once daily
Glatopa has been determined by the FDA to be therapeutically
equivalent to daily COPAXONE 20 mg, and is an "AP" rated,
fully-substitutable product. As a therapeutically equivalent
generic product, once daily Glatopa contains the same active
ingredients, route of administration, strength, and dosage form,
and can be substituted with the full expectation that Glatopa will
produce the same clinical effect and safety profile as daily
COPAXONE 20 mg. Daily COPAXONE 20 mg is one of the leading products
marketed to treat multiple sclerosis, and is frequently prescribed
as a first-line therapy in newly diagnosed patients.
About Momenta Momenta Pharmaceuticals is a
biotechnology company specializing in the detailed structural and
functional analysis of complex drugs and is headquartered in
Cambridge, MA. Momenta is applying its technology to the
development of generic versions of complex drugs, biosimilar and
potentially interchangeable biologics, and to the discovery and
development of novel therapeutics for oncology and autoimmune
indications.
To receive additional information about Momenta, please visit
the website at www.momentapharma.com, which does not form a part of
this press release. The company's logo, trademarks, and service
marks are the property of Momenta Pharmaceuticals, Inc. All other
trade names, trademarks, or service marks are property of their
respective owners.
COPAXONE is a registered trademark of Teva Pharmaceuticals.
Glatopa is a trademark of Novartis AG.
CONTACT: Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Media Relations:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024